Distribution of N-acetyltransferase type 1 (NAT1) genotypes and alleles in a Turkish population

Genetics and Molecular Biology

Volumn 27, Issue 2, 2004, Pages 162-164

  Arslan, Serdal ^a   Degerli, Naci ^a   Bardakci, Fevzi ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Genetic polymorphism; Molecular epidemiology; NAT1 gene; Turkish population

Indexed keywords

ACYLTRANSFERASE;

ARTICLE; CAUCASIAN; CHROMOSOME 8P; ENZYME ACTIVITY; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC CODE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTRON; POPULATION GENETICS; TURKEY (REPUBLIC); WILD TYPE;

EID: 30644466230     PISSN: 14154757     EISSN: 16784685     Source Type: Journal    
DOI: 10.1590/S1415-47572004000200005     Document Type: Article

References (24)

1. * 10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 55:5226-5229.
2. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, Elder J, Hendrickse C, Duncan H and Strange RC (1995b) Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk for colorectal cancer. Cancer Res 55:3537-3542.
3. Bruhn C, Brockmöller J, Cascorbi I, Roots I and Borchert HH (1999) Correlation between genotype and phenotype of the human arylamine N-Acetyltransferase Type 1 (NAT1). Biochem Pharmacol 58:1759-1764.
4. Butcher NJ, Ilett KF and Minchin RF (1998) Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560A mutations. Pharmacogenetics 8:67-72.
5. Deguchi T, Mashimo M and Suzuki T (1990) Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 265:12757-12760.
6. *. Mol Pharmacol 58:288-299.
7. Grant DM, Vohra P, Avis Y and Ima A (1992) Detection of a new polymorphism of human arylamine N-acetyltransferase NAT1 using p-aminosalicylic acid as an in vivo probe. J Basic Clin Physiol Pharmacol 3(suppl.):244.
8. Hein DW, Grant DM and Sim E (2000) Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics 10:291-292.
9. Henning S, Cascorbi I, Münchow B, Jahnke V and Roots I (1999) Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics 9:103-111.
10. Hughes NC, Janezic SA, MacQuen KL, Jewett MAS, Castranio T, Bell DA and Grand DM (1998) Identification and characterization of variant alleles of human N-acetyltransferase NAT1 with defective function using p-aminosalicylate as in-vivo and in-vitro probe. Pharmacogenetics 8:55-66.
11. Jourenkova-Mironova N, Wikman H, Bouchardy C, Mitrunen K, Dayer P, Benhamous S and Hyrvonen A (1999) Role of arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2) genotypes in susceptibility to oral/pharyngeal and laryngeal cancers. Pharmacogenetics 9:533-537.
12. Katoh T, Boissy R, Nagata N, Kitagawa K, Kuroda Y, Itoh H, Kawamoto T and Bell DA (2000) Inherited polymorphism in the N-actyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. Int J Cancer 85:46-49.
13. Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K and Bell DA (1998) A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis 19:1803-1807.
14. Lin HJ, Probst-Hensch NM, Hughes NC, Sakamato GT, Louie AD, Kau IH, Lin BK, Lee DB, Lin J, Frankl HD, Lee ER, Hardy S, Grant DM and Haile RW (1998) Variants of N-acetyltransferase NAT1 and a case-control study of colerectal adenomas. Pharmacogenetics 8:269-281.
15. Lo-Guidice J-M, Allorge D, Chevalier D, Herve D, Fazio F, Lafitte JJ and Broly F (2000) Molecular analysis of the N-acetyltransferase 1 (NAT1) using polymerase chain reaction-restriction-fragment single strand conformation polymorphism assay. Pharmacogenetics 10:293-300.
16. Loktionov A, Moore W, Spencer SP, Vorster H, Nell T, O'Neill IK, Bringham SA and Cummings JH (2002) Differences in N-acetylation genotypes between Caucasians and Black South Africans: implications for cancer prevention. Cancer Detect Prev 26:15-22.
17. Olshan AF, Wiessler M, Watson MA and Bell DA (2000) GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphism tabacco use, and the risk of head neck cancer. Cancer Epidemiol Biomarkers Prev 9:185-191.
18. Taylor JA, Umbach D, Stephan E, Paulson D, Robertson C, Mohler JL and Bell DA (1995) Role of the N-acetylation polymorphism at NAT1 and NAT2 in smoking-associated bladder cancer. Proc Am Assoc Cancer Res 36:282.
19. Vatsis KP and Weber WW (1993) Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 301:71-76.
20. Wikman H, Thiel S, Jäger B, Schmezer P, Spiegelhalder B, Edler L, Dienemann H, Kayser K, Schulz V, Drings P, Bartsch H and Risch A (2001) Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non small cell lung cancer susceptibility. Pharmacogenetics 11:157-168.
21. Yang M, Katoh T, Delongchamp R, Ozowa S, Kohshi K and Kawamoto T (2000) Relationship between NAT1 genotype and phenotype in a Japanese population. Pharmacogenetics 10:225-232.
22. Zenser TV, Lakshmi VM, Rustan TD, Doll MA, Deitz AC, Davis BB and Hein DW (1996) Human N-acetylation of benzidine: role of NAT1 and NAT2. Cancer Res 56: 3941-3947.
23. Zhao B, Lee EJ, Yeoh PN and Gong NH (1998) Detection of mutations and polymorphism of N-acetyltransferase 1 gene in Indian, Malay and Chinese populations. Pharmacogenetics 8:299-304.
24. Zheng W, Dietz A, Chambell D, Wen W-Q, Cerhan J, Sellers T, Folsom A and Hein DW (1999) N-Acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8:233-239.